chronic
obstruct
pulmonari
diseas
copd
affect
million
peopl
unit
state
fourth
lead
caus
death
account
death
worldwid
copd
sixth
lead
caus
death
petti
ward
et
al
halbert
et
al
halpern
et
al
wouter
condit
top
caus
death
increas
preval
mortal
pauwel
et
al
mannino
et
al
petti
stoller
global
burden
diseas
studi
undertaken
world
bank
world
health
organ
conclud
copd
becom
third
lead
caus
death
worldwid
rank
rel
number
disabilityadjust
lifeyear
lost
increas
gulsvik
current
oxygen
therapi
hypoxem
patient
cigarettesmok
cessat
intervent
known
alter
natur
histori
copd
although
exact
definit
acut
exacerb
copd
aecopd
remain
controversi
pauwel
et
al
gener
accept
definit
sustain
worsen
patient
condit
stabl
state
beyond
normal
daytoday
variat
acut
onset
necessit
chang
regular
medic
patient
underli
copd
rodriguesroisin
acut
exacerb
copd
aecopd
account
million
offic
visit
year
us
niederman
et
al
sethi
gonzal
et
al
account
total
cost
copd
us
europ
ward
et
al
mcguir
et
al
strassel
et
al
andersson
et
al
miravitl
et
al
acut
exacerb
copd
result
sixth
highest
use
hospit
bed
daysyr
us
million
sixth
highest
number
day
lost
work
million
druss
et
al
aecopd
major
sourc
healthcar
expenditur
halpern
et
al
cost
particularli
evid
aecopd
requir
hospit
miravitl
et
al
oostenbrink
ruttenvan
molken
neg
implic
aecopd
highlight
numer
investig
review
eighteen
studi
confirm
aecopd
worsen
healthrel
qualiti
life
hrql
schmier
et
al
twoyear
longitudin
studi
note
frequent
exacerb
deleteri
effect
health
statu
patient
moder
diseas
forc
expiratori
volum
one
second
predict
miravitl
et
al
greatest
improv
hrql
occur
first
four
week
singl
episod
although
continu
improv
occur
week
convers
recurr
aecopd
markedli
attenu
improv
spencer
et
al
aecopd
also
result
measur
albeit
modest
acut
effect
pulmonari
function
seemung
et
al
modest
improv
pulmonari
function
particularli
lung
volum
report
first
sever
week
therapi
initi
parker
et
al
stevenson
et
al
repeat
aecopd
associ
loss
pulmonari
function
decrement
rang
mlyr
patient
frequent
episod
donaldson
et
al
kanner
et
al
thu
aecopd
associ
signific
healthcar
expenditur
deterior
hrql
may
sustain
appreci
deterior
pulmonari
function
accordingli
prevent
aecopd
reduc
sever
favor
clinic
physiolog
econom
effect
copd
patient
past
sever
year
numer
studi
confirm
import
role
inflamm
airway
lung
parenchyma
copd
hill
et
al
sethi
aaron
et
al
gompertz
et
al
wedzicha
pietila
thoma
white
et
al
mani
advoc
central
pathogen
role
inflammatori
respons
hogg
et
al
shapiro
ingenito
trave
donnelli
wouter
inflammatori
respons
contribut
increas
oxid
stress
note
aecopd
tsoumakid
et
al
neutrophil
eosinophil
inflamm
describ
multitud
inflammatori
mediat
implic
includ
leukotrien
tumor
necrosi
granulocytemacrophag
coloni
stimul
factor
gmcsf
regul
upon
activ
normal
cell
expressedsecret
rant
hill
et
al
sethi
gompertz
et
al
roland
et
al
white
et
al
one
group
follow
patient
copd
emphysemat
phenotyp
year
develop
aecopd
associ
expector
sputum
adequ
analysi
fujimoto
et
al
aecopd
total
sputum
cell
lymphocyt
neutrophil
eosinophil
neutrophil
elastas
eosinophil
cation
protein
ecp
rant
increas
compar
stabl
state
prospect
studi
use
bronchoscop
techniqu
confirm
increas
express
rant
surfac
epithelium
subepitheli
lymphomononuclear
cell
increas
number
neutrophil
well
increas
aecopd
zhu
et
al
qiu
et
al
drost
et
al
collect
data
confirm
local
inflammatori
process
increas
oxid
stress
statu
exacerb
novel
pathway
promulg
inflammatori
respons
recent
defin
ito
et
al
copd
progress
lung
infiltr
activ
macrophag
rutger
et
al
amin
et
al
caramori
adcock
lymphocyt
saetta
et
al
shaughnessi
et
al
hogg
et
al
macrophag
lymphocyt
increas
airway
alveoli
copd
di
stefano
et
al
shapiro
ingenito
preval
two
cell
type
rather
neutrophil
previous
suspect
correl
sever
airflow
obstruct
di
stefano
et
al
shaughnessi
et
al
kemeni
et
al
hill
et
al
turato
et
al
hogg
et
al
emphysema
finkelstein
et
al
russel
culpitt
et
al
russel
thorley
et
al
macrophag
key
cell
innat
immun
system
secret
cytokin
chemokin
stimul
pathogenassoci
molecular
pattern
pamp
mani
lung
lymphocyt
type
cytokineproduc
cell
saetta
et
al
majo
et
al
grumelli
et
al
cell
predomin
evid
studi
use
chronic
bronchiti
entri
criteria
saetta
et
al
less
evid
studi
design
select
chronic
bronchiti
hogg
et
al
although
macrophag
cell
could
synergist
contribut
progress
lung
destruct
copd
sever
way
barn
et
al
exact
mechan
remain
unproven
system
natur
copd
aecopd
recent
document
agusti
plasma
fibrinogen
creactiv
protein
concentr
increas
aecopd
dev
et
al
wedzicha
roland
et
al
hurst
et
al
variou
infecti
noninfecti
stimuli
stimul
inflammatori
respons
associ
aecopd
environment
pollut
includ
particul
matter
nonparticul
gase
provok
inflammatori
respons
invitro
invivo
devalia
et
al
ohtoshi
et
al
rudel
et
al
epidemiolog
studi
suggest
increas
respiratori
symptom
mortal
time
increas
air
pollut
sunyer
et
al
garciaaymerich
et
al
sunyer
et
al
despit
data
larg
proport
aecopd
felt
reflect
infect
whether
bacteri
viral
sethi
viral
infect
well
recogn
caus
aecopd
wilkinson
et
al
johnston
frequent
report
agent
includ
rhinoviru
coronaviru
influenza
parainfluenza
adenoviru
respiratori
syncyti
viru
rsv
human
metapneumoviru
stott
et
al
gump
et
al
seemung
et
al
greenberg
rhode
et
al
tan
et
al
pletz
et
al
wedzicha
hamelin
et
al
atyp
infecti
agent
includ
chalmydia
pneumonia
mycoplasma
pneumonia
legionella
speci
report
caus
aecopd
although
major
data
involv
c
pneumonia
beati
et
al
blasi
et
al
mogulkoc
et
al
karnak
et
al
lieberman
et
al
seemung
et
al
etiolog
role
bacteria
individu
aecopd
episod
subject
much
controversi
hirschmann
murphi
et
al
recent
comprehens
review
highlight
evolut
concept
sethi
murphi
sethi
sputum
cultur
classic
methodolog
approach
identifi
potenti
pathogen
bacteria
aecopd
frequent
isol
organ
nontyp
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
less
frequent
identifi
organ
includ
haemophilu
parainfluenza
staphylococcu
aureu
pseudomona
aeruginosa
gramneg
rod
pseudomona
spp
enter
gramneg
rod
identifi
sputum
patient
greater
airflow
obstruct
eller
et
al
miravitl
et
al
prior
use
antimicrobi
agent
monso
et
al
bronchoscop
studi
use
bronchoalveolar
lavag
protect
specimen
brush
confirm
potenti
pathogen
bacteria
identifi
mani
copd
patient
baselin
aecopd
fagon
et
al
monso
et
al
pela
et
al
soler
et
al
analysi
pool
data
six
publish
studi
confirm
high
frequenc
colon
stabl
copd
patient
contrast
healthi
subject
clear
shift
higher
potenti
pathogen
organ
load
note
aecopd
rosel
et
al
importantli
sever
group
demonstr
bacteri
colon
defin
sputum
cultur
associ
greater
sputum
system
inflammatori
respons
frequent
clinic
aecopd
episod
greater
symptom
wors
health
statu
soler
et
al
bresser
et
al
hill
et
al
patel
et
al
banerje
et
al
novel
methodolog
approach
provid
even
compel
data
implic
bacteri
pathogen
aecopd
longitudin
use
sputum
cultur
molecular
type
bacteri
pathogen
isol
sputum
demonstr
acquisit
bacteri
strain
patient
previous
infect
associ
greater
twofold
increas
risk
exacerb
sethi
et
al
although
identif
new
strain
nontyp
h
influenza
associ
symptomat
exacerb
major
patient
collabor
work
highlight
inher
differ
new
h
influenza
strain
associ
symptomat
exacerb
lead
greater
neutrophil
recruit
adher
epitheli
cell
greater
releas
epitheli
cell
cultur
compar
associ
clinic
respons
chin
et
al
similar
approach
confirm
increas
risk
aecopd
catarrhali
murphi
et
al
immun
respons
one
microbi
pathogen
util
recent
defin
role
bacteria
individu
aecopd
episod
methodolog
approach
wide
report
h
influenza
catarrhali
musher
et
al
yi
et
al
bakri
et
al
sethi
murphi
et
al
examin
interact
bacteri
viral
infect
bandi
et
al
one
studi
exacerb
associ
evid
acut
viral
infect
wherea
associ
develop
new
serum
igg
homolog
h
influenza
isol
evid
viral
infect
identifi
exacerb
bandi
et
al
data
show
viral
bacteri
infect
coexist
symptomat
aecopd
although
anteced
viral
infect
requir
h
influenza
associ
exacerb
given
compel
data
bacteri
infect
like
etiolog
approxim
aecopd
surpris
antimicrobi
therapi
intens
studi
diseas
numer
placebocontrol
trial
antibiot
aecopd
publish
systemat
review
suggest
modest
treatment
effect
favor
antimicrobi
therapi
bach
et
al
mccrori
et
al
saint
et
al
saint
colleagu
examin
nine
placebo
control
trial
conclud
small
statist
signific
improv
antibiot
therapi
especi
signific
patient
low
baselin
flow
rate
american
colleg
chest
physician
american
colleg
physician
american
societi
intern
medicin
systemat
analyz
random
placebocontrol
studi
antibiot
treatment
also
conclud
antibiot
benefici
bach
et
al
mccrori
et
al
snow
et
al
addit
studi
publish
sinc
systemat
review
publish
allegra
colleagu
note
overal
clinic
respons
rate
improv
amoxicillinclavulan
versu
placebo
multicent
trial
welldefin
aecopd
respons
clearli
vari
sever
baselin
airflow
obstruct
greatest
differ
placebo
antimicrobi
agent
note
patient
lowest
nouria
colleagu
demonstr
dramat
improv
ofloxacin
therapi
compar
placebo
group
patient
sever
copd
admit
respiratori
failur
base
data
recent
intern
guidelin
incorpor
recommend
aecopd
patient
like
bacteri
infect
like
benefit
antimicrobi
agent
blasi
et
al
patient
least
two
cardin
symptom
aecopd
increas
dyspnea
increas
sputum
product
andor
chang
sputum
color
experi
benefit
antibiot
therapi
anthonisen
et
al
exacerb
associ
sputum
purul
may
also
like
benefit
antibiot
treatment
stockley
et
al
wilson
increas
sputum
purul
clearli
associ
bacteri
growth
sputum
sampl
allegra
et
al
blasi
et
al
measur
serum
procalcitonin
level
recent
suggest
defin
aecopd
patient
higher
likelihood
bacteri
infect
reichenberg
et
al
christcrain
et
al
henc
avail
data
suggest
antimicrobi
therapi
provid
benefit
care
select
patient
sever
diseas
sever
exacerb
numer
control
trial
compar
newer
agent
establish
one
studi
gener
design
noninferior
trial
registr
purpos
therefor
provid
limit
compar
inform
regard
clinic
respons
variou
antimicrobi
class
miravitl
torr
sethi
wilson
surprisingli
clinic
respons
trial
gener
similar
among
differ
antimicrobi
class
howev
recent
trial
use
novel
experiment
design
suggest
interest
differ
differ
antimicrobi
class
exampl
defin
bacteri
erad
sputum
cultur
white
colleagu
note
patient
persist
bacteria
ten
day
cours
antimicrobi
therapi
exhibit
elev
sputum
inflammatori
marker
addit
investig
suggest
rapid
resolut
symptom
may
seen
quinolon
contrast
compar
agent
miravitl
et
al
martinez
et
al
data
suggest
erad
bacteri
pathogen
may
associ
import
clinic
outcom
provoc
data
revolv
around
find
agent
may
lengthen
diseasefre
interv
dfi
ie
time
exacerb
anzueto
et
al
saint
et
al
chodosh
wilson
antimicrobi
therapi
complet
erad
bacteria
associ
reduc
inflamm
white
et
al
agent
result
greater
symptomat
resolut
better
longterm
clinic
outcom
anzueto
et
al
chodosh
wilson
base
consider
aecopd
clinic
trial
increasingli
incorpor
assess
differ
antibiot
affect
dfi
martinez
et
al
earli
studi
demonstr
equival
antibiot
shortterm
clinic
respons
although
posthoc
analysi
suggest
failur
clear
organ
sputum
posttherapi
associ
shorter
dfi
chodosh
et
al
wilson
colleagu
note
fewer
recurr
aecopd
gemifloxacin
compar
clarithromycin
p
mosaic
studi
investig
contrast
moxifloxacin
variou
compar
cefuroxim
clarithromycin
amoxicillin
wilson
et
al
although
antibiot
result
equival
shortterm
clinic
respons
moxifloxacintr
patient
requir
fewer
addit
antibiot
experienc
longer
dfi
contrast
lode
colleagu
demonstr
differ
levofloxacin
clarithromycin
respect
dfi
although
patient
popul
bit
less
ill
thu
effect
antibiot
class
dfi
remain
crucial
endpoint
futur
studi
aecopd
gener
macrolid
provid
adequ
coverag
frequent
identifi
pathogen
aecopd
martinez
although
differ
among
compound
h
influenza
activ
evid
exampl
azithromycin
appear
improv
bacteriolog
clinic
activ
rel
clarithromycin
martinez
et
al
role
macrolid
aecopd
therapi
remain
controversi
although
gener
includ
publish
guidelin
balter
et
al
pauwel
et
al
martinez
woodhead
et
al
blasi
et
al
guidelin
usual
advoc
stratif
patient
likelihood
clinic
failur
macrolid
therapi
suggest
patient
milder
underli
diseas
low
likelihood
infect
organ
cover
standard
antibiot
regimen
eg
p
aeruginosa
drugresist
bacteria
host
factor
predict
treatment
failur
macrolid
macrocycl
lacton
consist
greater
ring
larg
class
compound
compris
natur
substanc
isol
fungi
organ
well
synthet
molecul
similar
structur
jain
danzig
commonli
clinic
use
agent
semisynthet
ring
antibiot
relat
erythromycin
figur
includ
erythromycin
roxithromycin
clarithromycin
typic
member
class
azithromycin
prototyp
compound
labro
macrolid
antibiot
bind
ribosom
prokaryot
eukaryot
inhibit
transpeptid
transloc
nascent
peptid
macrolid
good
bioavail
oral
rout
superb
tissu
penetr
favor
sideeffect
profil
prolong
tissu
persist
reason
broad
efficaci
gramposit
gramneg
mycobacteri
chlamydi
mycoplasm
legionella
speci
macrolid
well
establish
therapi
respiratori
infect
macrolid
exert
broadrang
immunomodulatori
effect
mammalian
cell
vitro
vivo
comprehens
review
other
briefli
summar
tabl
illustr
figur
zalewskakaszubska
gorska
labro
tsai
standiford
among
mani
activ
macrolid
shown
exert
effect
wide
rang
cell
includ
nasal
bronchial
epitheli
cell
alveolar
macrophag
monocyt
eosinophil
neutrophil
lymphocyt
effect
signal
pathway
includ
desaki
et
al
kikuchi
et
al
evid
figur
macrolid
exert
host
effect
collect
limit
tissu
damag
neutrophil
addit
effect
chemoattract
includ
inhibit
oxid
burst
impair
degranul
increas
rate
neutrophil
apoptosi
also
evid
macrolid
decreas
mucu
viscos
tamaoki
et
al
suppress
angiogenesi
yasunami
hayashi
importantli
immunomodulatori
effect
evid
concentr
attain
clinic
lowdos
administr
seen
use
macrolid
immunomodulatori
effect
share
agent
although
case
effect
vari
among
individu
compound
exampl
roxithromycin
appear
exhibit
consist
effect
vitro
vivo
agen
et
al
scaglion
rossoni
similarli
clarithromycin
azithromycin
induc
apoptosi
peripher
blood
lymphocyt
qualit
greater
extent
josamycin
ishimatsu
et
al
henc
macrolid
mani
properti
could
mitig
neutrophil
inflamm
central
airway
damag
might
also
improv
aspect
airflow
obstruct
macrolid
also
exert
divers
action
suppress
microbi
virul
factor
shryock
et
al
pecher
wozniak
keyser
although
p
aeruginosa
possess
high
innat
resist
vitro
mic
macrolid
accumul
within
microb
time
suppress
elabor
elastas
lecithinas
pyocyanin
macrolid
also
alter
structur
lp
outer
membran
protein
net
effect
decreas
microbi
adhes
host
cell
hibit
algin
product
macrolid
destroy
pseudomon
biofilm
facilit
kill
antibiot
final
subinhibitori
concentr
macrolid
imped
microbi
motil
p
mirabili
p
aeruginosa
inhibit
flagellin
synthesi
importantli
activ
also
common
macrolid
seen
use
rokitamycin
ring
macrolid
potent
bactericid
activ
suscept
organ
furthermor
differ
among
individu
agent
report
azithromycin
exhibit
greatest
effect
quorum
sens
molinari
et
al
given
immunomodulatori
properti
uniqu
effect
bacteri
pathogen
macrolid
antimicrobi
agent
potenti
serv
uniqu
role
manag
chronic
inflammatori
lung
disord
includ
copd
macrolid
increasingli
use
immunomodulatori
properti
wide
rang
chronic
disord
discuss
detail
result
chronic
inflammatori
pulmonari
disord
highlight
goal
present
rational
potenti
use
copd
asthma
number
biolog
featur
distinct
copd
douw
et
al
sutherland
martin
macrolid
antibiot
util
asthma
forti
year
exampl
troleandomycin
tao
extens
studi
steroidspar
agent
asthma
niven
argyro
inconclus
result
evan
et
al
investig
examin
wide
avail
macrolid
agent
wide
report
outcom
modest
improv
bronchial
hyperrespons
miyatak
et
al
shimizu
et
al
kamoi
et
al
amayasu
et
al
kostadima
et
al
clinic
respons
difficult
judg
uncontrol
studi
garey
et
al
sever
control
trial
publish
recent
cochran
systemat
review
richeldi
et
al
gener
studi
document
modest
symptomat
improv
littl
chang
standard
spirometr
indic
shoji
et
al
amayasu
et
al
investig
provid
mechanist
data
regard
effect
macrolid
therapi
patient
asthma
kraft
colleagu
note
improv
patient
evid
polymeras
chain
reaction
pcr
mycoplasma
chlamydia
upper
lower
respiratori
tract
specimen
patient
pcrposit
patient
treat
clarithromycin
experienc
decreas
mrna
bal
fluid
mrna
airway
tissu
pcrneg
patient
treat
clarithromycin
exhibit
decreas
mrna
bal
mrna
airway
tissu
signific
chang
seen
subject
treat
placebo
black
colleagu
conduct
multicent
multin
studi
adult
mild
moder
asthma
serolog
evid
c
pneumonia
infect
random
patient
roxithromycin
mg
bid
placebo
six
week
modest
increas
peak
expir
flow
note
macrolid
treat
patient
six
week
daytim
nighttim
symptom
show
nonsignific
improv
improv
qualiti
life
score
differ
two
studi
may
reflect
dispar
patient
characterist
baselin
differ
macrolid
administ
differ
definit
atyp
infect
point
may
import
interpret
data
copd
patient
chronic
infect
chlamydia
felt
import
blasi
et
al
bronchiectasi
disord
bronchi
bronchiol
manifest
cough
chronic
sputum
product
dyspnea
wheez
barker
cornerston
therapi
includ
earli
identif
treatment
acut
exacerb
suppress
microbi
load
treatment
underli
condit
promot
bronchial
hygien
control
bronchial
hemorrhag
surgic
resect
extrem
damagedfoc
diseas
reduct
excess
pulmonari
inflamm
barker
like
bronchiectasi
involv
viciou
cycl
infect
subsequ
inflamm
mediat
releas
investig
confirm
intens
cellular
infiltr
mononuclear
cell
lymphocyt
macrophag
promin
neutrophilia
increas
express
gaga
et
al
increas
express
potent
chemoattract
also
report
angril
et
al
richmaneisenstat
et
al
tsang
et
al
addit
patient
colon
potenti
pathogen
organ
experi
greater
inflammatori
respons
includ
higher
bal
neutrophil
count
higher
bal
concentr
elastas
myeloperoxidas
angril
et
al
bronchiectasi
patient
p
aeruginosa
sputum
sever
impair
pulmonari
function
greater
sputum
volum
ho
et
al
patient
also
appear
exhibit
highest
concentr
tsang
et
al
evid
bronchiectasi
character
augment
airway
inflamm
appear
relat
bacteri
colon
organ
load
differ
bacteri
speci
small
number
studi
examin
effect
chronic
macrolid
therapi
bronchiectasi
unrel
cystic
fibrosi
week
roxithromycin
mgkg
bid
children
bronchiectasi
increas
airway
hyperreact
experienc
littl
chang
experienc
improv
sputum
purul
airway
respons
koh
et
al
placebocontrol
trial
tsang
colleagu
administ
erythromycin
mg
bid
eight
week
patient
bronchiectasi
tsang
et
al
p
aeruginosa
identifi
baselin
ten
patient
h
influenza
eleventh
patient
treat
macrolid
experienc
improv
spirometri
sputum
volum
parallel
improv
sputum
pathogen
sputum
leukocyt
level
tsang
et
al
tagaya
colleagu
note
improv
sputum
product
patient
bronchiectasi
n
chronic
bronchiti
n
treat
clarithromycin
mgday
compar
patient
treat
amoxicillin
cefaclor
davi
wilson
examin
thrice
weekli
initi
load
azithromycin
therapi
patient
bronchiectasi
greater
four
exacerb
previou
month
persist
symptom
modest
improv
note
pulmonari
function
although
symptom
score
acut
exacerb
decreas
find
independ
p
aeruginosa
colon
small
crossov
studi
cymbala
colleagu
note
decreas
acut
exacerb
rate
mean
sputum
volum
chang
pulmonari
function
twice
weekli
azithromycin
therapi
six
month
data
particularli
german
given
frequent
develop
bronchiectasi
follow
aecopd
brien
et
al
robust
bodi
literatur
emerg
demonstr
macrolid
antibiot
benefici
treatment
cystic
fibrosi
cf
lung
diseas
equi
et
al
wolter
et
al
saiman
et
al
southern
et
al
numer
studi
strengthen
conclus
excess
inflamm
cf
airway
khan
colleagu
note
higher
inflammatori
cell
mediat
infant
cf
even
evid
bacteri
infect
identifi
augment
inflammatori
respons
may
intrins
cf
airway
epitheli
cell
dimango
colleagu
note
respons
pseudomona
epitheli
cell
mutat
cystic
fibrosi
gene
cftr
elabor
higher
level
inflammatori
mediat
cell
normal
cftr
inflammatori
pulmonari
disord
high
preval
chronic
airway
infect
occur
cf
p
aeruginosa
appear
preval
organ
patient
infect
year
age
trulock
et
al
infect
major
consequ
surviv
cf
patient
harbor
pseudomona
aeruginosa
shorter
cf
patient
uninfect
pseudomona
seri
studi
confirm
benefit
macrolid
therapi
cf
jaff
colleagu
perform
openlabel
studi
daili
azithromycin
children
cf
uk
note
modest
improv
spirometri
azithromycin
therapi
first
wellconstruct
clinic
trial
azithromycin
cf
report
wolter
colleagu
sixti
cf
patient
mean
age
year
randomli
assign
doubleblind
fashion
mg
azithromycin
daili
placebo
month
modest
improv
favor
macrolid
note
spirometri
requir
intraven
antibiot
treatment
acut
exacerb
qualiti
life
equi
colleagu
perform
random
doubleblind
placebocontrol
crossov
studi
cf
patient
age
rang
year
patient
receiv
daili
azithromycin
adjust
bodi
weight
placebo
month
washout
period
patient
cross
altern
therapi
month
modest
improv
note
favor
azithromycin
howev
differ
fvc
pulmonari
exacerb
rate
antibiot
use
chang
exercis
toler
qualiti
wellb
bacteri
cultur
densiti
sputum
level
neutrophil
elastas
largest
trial
macrolid
therapi
cf
complet
saiman
colleagu
perform
multicent
random
doubleblind
placebocontrol
studi
patient
year
age
chronic
infect
p
aeruginosa
percent
predict
patient
treat
weightadjust
azithromycin
dosag
week
treatment
percent
predict
improv
azithromycin
group
wherea
declin
placebo
group
p
furthermor
azithromycintr
patient
less
like
experi
exacerb
treat
placebo
hr
ci
p
subsequ
posthoc
analys
confirm
improv
secondari
endpoint
independ
chang
saiman
et
al
mechan
favor
macrolid
effect
remain
controversi
like
multifactori
martinez
simon
grow
evid
macrolid
may
benefici
directli
alter
p
aeruginosa
biolog
jaff
bush
nguyen
et
al
wagner
et
al
suggest
mechan
includ
microbicid
effect
p
aeruginosa
stationari
oppos
exponenti
growth
phase
reduct
elabor
virul
factor
alter
biofilm
format
decreas
bacteri
adher
epitheli
cell
inhibit
bacteri
motil
provid
synergist
effect
antibiot
martinez
simon
like
benefici
antiinflammatori
effect
also
play
role
tabl
jaff
bush
nguyen
et
al
martinez
simon
taken
togeth
avail
data
confirm
macrolid
result
clinic
improv
patient
sever
chronic
inflammatori
lung
diseas
associ
frequent
bacteri
colon
chronic
infect
data
provid
rational
expans
studi
macrolid
therapi
common
inflammatori
airway
disord
includ
copd
given
import
inflamm
bacteri
infect
pathogenesi
copd
exacerb
evid
macrolid
may
offer
uniqu
advantag
diseasemodifi
agent
effect
could
multifactori
figur
possibl
support
three
older
publish
studi
first
random
trial
contrast
moxifloxacin
clarithromycin
acut
exacerb
confirm
clinic
respons
clarithromycin
patient
despit
achiev
bacteriolog
erad
wilson
et
al
immunomodulatori
effect
macrolid
suggest
explain
discrep
find
wilson
second
suzuki
colleagu
report
result
openlabel
prospect
random
trial
erythromycin
therapi
mgday
versu
riboflavin
mgday
twelv
month
copd
patient
liter
cours
therapi
risk
frequenc
experienc
common
cold
use
predefin
standard
definit
subsequ
acut
exacerb
prospect
evalu
tabl
enumer
signific
benefit
note
macrolid
therapi
although
result
intrigu
unblind
data
collect
limit
strength
conclus
studi
third
gomez
colleagu
identifi
patient
long
histori
chronic
bronchiti
year
frequenc
five
episod
per
year
least
two
respiratori
hospit
previou
year
patient
treat
azithromycin
mg
daili
three
day
everi
day
septemb
may
compar
similar
retrospect
group
untreat
copd
patient
although
baselin
differ
treat
patient
control
patient
cours
followup
macrolid
treat
patient
experienc
fewer
exacerb
hospit
per
year
tabl
unexpectedli
exacerb
azithromycin
treat
group
experienc
infect
pneumonia
n
p
aeruginosa
n
k
pneumonia
n
interestingli
within
first
day
prophylact
treatment
exacerb
caus
pneumonia
isol
diminish
suscept
macrolid
penicillin
control
group
predomin
isol
exacerb
includ
h
influenza
n
pneumonia
n
two
exhibit
diminish
sensit
azithromycin
studi
although
use
suboptim
uncontrol
design
suggest
benefici
respons
seen
chronic
macrolid
prophylaxi
highrisk
copd
patient
mechan
improv
address
could
relat
antibacteri
activ
particularli
regard
h
influenza
recent
two
group
report
small
control
studi
basyigit
colleagu
random
stabl
male
copd
patient
mean
age
yr
predict
clarithromycin
mg
bid
placebo
two
week
addit
standard
bronchodil
therapi
although
baselin
differ
note
treatment
group
clarithromycintr
patient
experienc
significantli
improv
sputum
inflammatori
marker
figur
wherea
physiolog
studi
chang
result
serum
inflammatori
marker
qualit
similar
two
group
second
control
studi
patient
moder
sever
copd
mean
age
yr
pred
random
three
month
clarithromycin
mg
sustain
releas
prepar
daili
placebo
banerje
et
al
contrast
previou
studi
patient
take
inhal
corticosteroid
clarithromycin
associ
signific
improv
st
georg
respiratori
questionnair
sgrq
symptom
score
unit
physic
function
score
unit
differ
overal
sgrq
score
shuttl
walk
distanc
spirometri
crp
level
rel
short
time
followup
five
total
aecopd
clarithromycin
placebo
group
differ
seen
quantit
sputum
cultur
obtain
stabl
state
figur
contrast
previou
studi
sputum
level
differ
clarithromycin
versu
placebo
treatment
although
modest
macrolideassoci
improv
sputum
neutrophil
differenti
neutrophil
chemotaxi
banerje
et
al
investig
propos
mechanist
rational
improv
chronic
macrolid
therapi
copd
patient
tagaya
colleagu
suggest
chronic
bronchiti
bronchiectasi
patient
treat
clarithromycin
mg
qd
seven
day
experienc
greater
decreas
sputum
volum
patient
treat
parnham
colleagu
treat
copd
patient
mean
liter
azithromycin
mg
daili
three
day
eight
placebo
azithromycin
result
earli
transient
increas
overal
nitrit
plu
nitrat
concentr
later
day
decreas
total
blood
leukocyt
count
serum
crp
oxid
burst
isol
blood
granulocyt
differ
note
sputum
inflammatori
marker
azithromycin
treat
placebotr
patient
potenti
risk
chronic
macrolid
therapi
patient
popul
macrolid
use
may
associ
increas
risk
subsequ
infect
macrolid
nonsuscept
bacteria
particularli
pneumonia
klugman
lonk
vanderkooi
et
al
increas
macrolidenonsuscept
pneumonia
report
chronic
erythromycin
aberg
et
al
kasahara
et
al
clarithromycin
kasahara
et
al
azithromycin
therapi
gomez
et
al
aberg
et
al
similarli
agent
may
associ
gastrointestin
intoler
saiman
et
al
basyigit
et
al
cymbala
et
al
cardiac
toxic
iannini
milberg
et
al
ototox
haydon
et
al
swanson
et
al
wallac
et
al
frequenc
sever
toxic
vari
agent
dose
durat
therapi
potenti
complic
high
preval
medic
comorbitidi
copd
patient
highlight
potenti
risk
chronic
empir
macrolid
therapi
patient
popul
macrolid
antibiot
assum
import
role
manag
aecopd
broadspectrum
coverag
excel
safeti
profil
increasingli
data
becom
avail
macrolid
benefici
effect
independ
antibacteri
activ
potent
antiinflammatori
effect
may
particularli
import
chronic
inflammatori
airway
disord
latter
action
may
greatest
benefit
select
patient
copd
disord
character
augment
pulmonari
inflamm
baselin
frequent
bacteri
colonizationinfect
recurr
exacerb
diseas
increas
lung
inflamm
role
chronic
macrolid
therapi
patient
requir
addit
studi
better
defin
seri
concern
includ
resolut
vital
question
requir
addit
welldesign
placebocontrol
trial
knowledg
three
larg
studi
current
ongo
yield
answer
vital
question
widespread
use
macrolid
prophylaxi
recommend
copd
patient
